Benjamin Cravatt III

Benjamin Franklin Cravatt III is a professor in and chair of the Department of Chemical Physiology at The Scripps Research Institute in La Jolla, California. Considered a co-inventor of activity based proteomics and a substantial contributor to research on the endocannabinoid system, he is a prominent figure in the nascent field of chemical biology. Cravatt was elected to the National Academy of Sciences in 2014, and the American Academy of Arts and Sciences in 2016. He is also a Cope Scholar and a Searle Scholar.

Cravatt's father was a dentist and his mother a dental hygenist, both of whom instilled in Cravatt an interest in biology as a child.

Cravatt entered Stanford University in 1988, graduating in 1992 with a BS in the Biological Sciences and a BA in History. He then received a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in 1996, where he worked under the joint supervision of Dale L. Boger and Richard Lerner. His early contributions to the cannabinoid field include identification and characterization of the endocannabinoid-terminating enzyme fatty acid amide hydrolase, FAAH, as well as the isolation of the novel soporific compound oleamide from cerebrospinal fluid.

Cravatt and colleagues pioneered the Activity-Based Protein Profiling (ABPP) chemical proteomic technology, which they used in 2010 to elucidate certain global proteomic features of cysteines. Cravatt's lab has since combined the ABPP technology with metabolomics.

Among the awards that Cravatt has received are the TR100 Award in 2002, the Eli Lilly Award in Biological Chemistry in 2004, the ASBMB-Merck Award in 2014 and the Sato Memorial Award in 2015. Cravatt also received an NCI MERIT grant in 2009.

Cravatt is a co-founder of Vividion Therapeutics, Abide Therapeutics and ActivX Biosciences. He currently serves as an Associate Editor for the Journal of the American Chemical Society, and previously served in the same capacity for Chemical Science.